Tag Archives: Novo Nordisk

Novo Buys Oral Obesity Asset from Lexicon; Corbus Ph1 CB1 Trial Update 

Two cardiometabolic-related news items have been observed: Novo Nordisk entered an exclusive licensing agreement with Lexicon for LX9851 (ASCL5 inhibitor; view press release); and Corbus Pharmaceuticals announced the dosing of the first patient in its Ph1 SAD/MAD trial evaluating its CB1 inverse agonist (view press release). Below, FENIX provides highlights and insights for the respective news items, including thoughts on Novo’s second deal in one week.

This content is for Read Less members only.
Already a member? Log in here

ATTD 2025 Key Press Releases (March 21)  

On the third day of ATTD 2025, five cardiometabolic-related news items have been observed from Novo Nordisk, Skye Bioscience, Terns Pharmaceuticals, Allurion Technologies, and Alnylam Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items. 

This content is for Read Less members only.
Already a member? Log in here

Novo Launches NovoCare DTP Platform; Lilly Manufacturing Pitches from States and Initiates TRIUMPH-6

Three cardiometabolic-related news items have been observed: Novo Nordisk announced it launched NovoCare and decreased Wegovy to $499/month, competing with Lilly’s LillyDirect model (view press release); Lilly has opened bids for US states to court Lilly manufacturing investments (view article; view website); and Lilly initiated the Ph3 TRIUMPH-6 retatrutide obesity maintenance study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how NovoCare is following Lilly’s lead for the new US commercial model.

This content is for Read Less members only.
Already a member? Log in here

AbbVie Enters Obesity Race; Novo Initiates New Drug Development AI Partnership; Biocon Launches Generic Liraglutide in UK

A series of cardiometabolic-related news items have been observed: AbbVie and Gubra announced a licensing agreement for a QW SC LA amylin agonist in obesity (view press release); Novo Nordisk and Gensaic entered into a new AI partnership for drug discovery (view press release); and Biocon has initiated a limited launch for its generic liraglutide in the UK (view press release). Below, FENIX provides highlights and insights for the respective news items

This content is for Read Less members only.
Already a member? Log in here

Lilly Stockpiles Orfoglipron; February CHMP Agenda Observed

Two cardiometabolic-related news items have been observed: Lilly has stockpiled $548M worth of orforglipron in a risky move ahead of the regulatory filing/approval (view 10-K); and the CHMP agenda (view here) for this month’s meeting (Feb 24-27) has been released. Below, FEINX provides highlights and insights for the respective news items.  

This content is for Read Less members only.
Already a member? Log in here